{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-032468","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.694998+00:00","generated_at":"2026-05-23T13:06:14.196640+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)","bullets":["Revenue surged 234% to $509,589 driven by licensing milestones.","Net loss improved to $4.90M from $7.79M; EPS improved 77% to $(0.42).","Operating expenses reduced 21% to $5.21M, R&D down 83%, SG&A down 58%.","Stock-based compensation increased to $2.77M from $0.19M to preserve cash.","Remaining milestone potential of up to $18.3M under existing licensing deals."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-032468","json":"https://secwatch.observer/filing/0001213900-25-032468.json","markdown":"https://secwatch.observer/filing/0001213900-25-032468.md","text":"https://secwatch.observer/filing/0001213900-25-032468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025032468/0001213900-25-032468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025032468/ea0238544-8ka1_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T13:06:14.196640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}